Scope and Claims of US Patent 4,138,475: Sustained-Release Propranolol Hydrochloride Film-Coated Spheroid Capsule Using Ethylcellulose/HPMC
US 4,138,475 is a composition-of-matter claim set focused on a sustained-release oral dosage built from film-coated propranolol-loaded spheroids placed into a hard gelatin capsule. The claim scope is narrow and highly parameterized around: (i) propranolol payload level, (ii) non-water-swellable microcrystalline cellulose (MCC) excipient choice and proportion, and (iii) film-coat polymer identity and viscosity grades using ethylcellulose plus hydroxypropyl methylcellulose (HPMC), plus defined coat solids percentage and optional plasticizer.
What does US 4,138,475 claim protect for sustained-release propranolol capsules?
Featured-snippet answer: The patent protects a hard gelatin capsule filled with film-coated propranolol MCC spheroids where the core contains 40 to 65 wt% propranolol (or a salt) in admixture with non-water-swellable MCC, and the coat is made of ethylcellulose and HPMC within defined ranges for polymer ratios, coat weight %, and optional plasticizer, with additional dependent limits on viscosity grades and specific drug loadings.
The independent claim is claim 1. Claims 2 to 9 narrow claim 1 through percentage ranges, coat composition ratios, viscosity grades, coat weight, plasticizer presence, and example-like drug load embodiments.
What is the independent claim 1 scope and how is it constrained?
Claim 1 elements (must all be present):
-
Dosage form / container
-
Contained dosage unit
- The capsule contains film coated spheroids (spheroidal pellets).
-
Core composition (pre-coating)
- Spheroids prior to coating comprise:
- 40 to 65 wt% propranolol or pharmaceutically-acceptable acid-addition salt; and
- non-water-swellable microcrystalline cellulose (MCC).
-
Coating polymers
- Film coat comprises:
- ethylcellulose and hydroxypropyl methylcellulose (HPMC).
Key constraint points:
- Propranolol level is bounded by 40–65 wt% in the uncoated spheroids.
- Excipient functionality is constrained to “non-water-swellable microcrystalline cellulose.” This is not generic MCC language; the claim ties to a particular grade/function (non-swellable in water).
- Film coat polymer system is constrained to ethylcellulose + HPMC. The claim does not allow substitution of either polymer with a different film former in claim 1.
- Claim 1 does not require:
- specific ratios of ethylcellulose:HPMC (that is provided in claim 6),
- specific coat weight %, or
- specific viscosity grades (that is in claims 4 and 5).
Claim 1 infringement reality:
- A competing product that uses a different core excipient (e.g., lactose, starch, or water-swellable MCC) likely falls outside claim 1 even if it uses propranolol and ethylcellulose/HPMC coat.
- A competing product that uses ethylcellulose alone or HPMC alone for coat also fails claim 1 because it requires both.
- A competing product that uses propranolol but places it in a matrix tablet rather than film-coated spheroids in a hard gelatin capsule likely fails on structure.
How do dependent claims 2 and 9 narrow core composition and drug loading?
Claim 2: tighter propranolol:MCC core ratio
- Uncoated spheroids contain:
- 50 to 60 wt% propranolol hydrochloride (salt form specified here), and
- 50 to 40 wt% non-water-swellable MCC.
Effect: Narrows claim 1’s 40–65 wt% band into a tighter 50–60 wt% window for the salt form (HCl) and complements must-satisfy MCC “non-water-swellable” limitation.
Claim 9: specific “consisting of” coat recipe plus specific capsule potency
Claim 9 is a highly specific embodiment with multiple “consisting of/consisting” style constraints:
- Core:
- 60 wt% propranolol hydrochloride
- 40 wt% non-water-swellable MCC
- Coat:
- film coat consists of:
- 90 wt% ethylcellulose (viscosity 50 cps at 20°C)
- 10 wt% HPMC (viscosity 6 cps at 20°C)
- coat comprises 9 to 10 wt% of the coated spheroids
- Capsule payload:
- 160 mg propranolol hydrochloride
Effect: Claim 9 is the narrowest in practice and will map to products manufactured to the same pellet recipe and capsule strength.
What is the film coat scope: polymers, ratios, viscosity grades, and coat weight?
Claim 6: ethylcellulose:HPMC ratio band
Film coat comprises:
- 80 to 100 wt% ethylcellulose
- 20 to 0 wt% HPMC
Effect: Covers a wide ratio band, including extremes: all ethylcellulose down to a 80/20 minimum of HPMC. It still requires both polymers unless HPMC is exactly 0 in the upper end interpretation. As written, it includes the possibility of 0 wt% HPMC, but claim 1 requires both polymers, so for any real infringement analysis the claim set logic matters:
- Under claim 1, both polymers are required.
- Under claim 6, the HPMC portion can trend to 0; but if HPMC truly is 0, there is a tension with claim 1.
Practically, the presence of HPMC in measurable amount supports meeting claim 1.
Claim 3: coat weight percent
- Film coat comprises 5 to 15 wt% of the coated spheroids.
Effect: Defines solids build-up. Many commercial sustained-release pellet systems use 2–6% or 15–25% coat solids, so this range can be a meaningful differentiator.
Claim 4 and 5: viscosity grades at 20°C
- Claim 4:
- ethylcellulose has 50 cps at 20°C
- Claim 5:
Effect: These are not generic “ethylcellulose / HPMC” claims. They lock the viscosity grades, which can be measured/derived from product datasheets or pharmacopeial/literature viscosity assignments. Competing products using different viscosity grades may avoid dependent claim coverage, while claim 1 could still be asserted if viscosity is not required for claim 1 (it is not).
Claim 7: plasticizer up to 20%
- Film coat contains up to 20 wt% plasticizer.
Effect: Includes typical plasticizers (commonly phthalates, triacetin-like materials, PEG-type plasticizers in other EC/HPMC systems). It does not require plasticizer, and the limit means very high plasticizer recipes may fall outside.
What specific capsule strengths and propranolol salt forms are covered?
Claim 8: dosage amount range
- Composition contains 100 to 200 mg of propranolol or pharmaceutically-acceptable acid-addition salt.
Effect: Covers common propranolol strengths used across IR/ER product lines, assuming the formulation is otherwise within claim 1.
Claim 9: specific 160 mg strength (example-like)
- 160 mg propranolol hydrochloride.
Effect: Creates a direct map to a single strength, if a commercial product uses exactly that amount per hard gelatin capsule and meets the core/coating parameterization.
What is the practical claim coverage matrix for infringement design-arounds?
Below is a condensed “all-elements” map for US 4,138,475 based on claim structure:
| Design element |
Claim 1 requirement |
Dependent narrowing (examples) |
Likely design-avoidance levers |
| Capsule format |
Hard gelatin capsule |
None specific to softgel |
Switch to tablets/mini-tablets or different container type (would attack element) |
| Core active |
40–65 wt% propranolol or acid-addition salt |
Claim 2: 50–60 wt% propranolol HCl; Claim 9: 60 wt% HCl |
Use different loading beyond bands; use different salt form may still be “acid-addition salt” but avoid exact wt% |
| Core excipient |
non-water-swellable MCC |
All dependent claims keep same excipient |
Use water-swellable excipient or different microcrystalline material functionality |
| Coat polymers |
ethylcellulose + HPMC |
Claim 6 ratio 80–100% EC / 0–20% HPMC |
Use EC-only coat or use different polymer pair; or change HPMC identity/viscosity grade |
| Coat solids % |
Not specified in claim 1 |
Claim 3: 5–15 wt% of coated spheroids |
Change coat weight outside band |
| EC viscosity |
Not required by claim 1 |
Claim 4: 50 cps at 20°C |
Use different EC viscosity grade |
| HPMC viscosity |
Not required by claim 1 |
Claim 5: 6 cps at 20°C |
Use different HPMC viscosity grade |
| Plasticizer |
Not required by claim 1 |
Claim 7: up to 20 wt% plasticizer |
Use >20 wt% plasticizer (but verify claim 1 still holds) |
| Capsule strength |
Not specified in claim 1 |
Claim 8: 100–200 mg; Claim 9: 160 mg |
Use strength outside bands (if otherwise covered) |
How does this patent fit within the broader sustained-release propranolol pellet landscape?
US 4,138,475 sits in a classic late-20th-century sustained-release strategy:
- drug-loaded cores (often MCC-based),
- layered film coating for diffusion control,
- capsule administration for dose flexibility.
Commercial differentiation for such systems typically comes from:
- selection of microcrystalline cellulose grade/function (non-water-swellable),
- the ethylcellulose/HPMC combination and ratio,
- coat solids loading and polymer viscosity grades,
- plasticizer package for film permeability and mechanical integrity.
This patent’s claim language is designed to lock those degrees of freedom.
What is the likely breadth of the patent claims (composition vs manufacturing process)?
Type of protection: The claims provided are composition/structure claims (product-by-structure) for a sustained-release composition:
- capsule + film-coated spheroids + defined core/coat parameterization.
No explicit method limitations appear in the claims quoted. The scope is framed around the finished product composition and physical structure of pellet and coat.
Business implication: A competitor aiming for “equivalent” sustained release performance must match the claimed structural/material parameter set to create infringement risk, not merely replicate dissolution behavior.
What patents or freedom-to-operate risks typically overlap with US 4,138,475?
A full freedom-to-operate landscape requires the complete US patent record set (application family, prosecution history, continuation claims, related patents for propranolol ER capsules, and any reexamination) and the Orange Book listing tied to specific propranolol ER NDA/ANDA products. That dataset is not provided here, and without it a complete and accurate “all-patents” landscape cannot be produced from the claim text alone.
What can be stated from the claim itself: the likely overlap zone for third-party claims includes:
- ethylcellulose/HPMC film-coating systems on drug-loaded spheroids,
- sustained-release propranolol HCl pellet compositions with MCC cores, and
- capsule fillable multiparticulate sustained-release propranolol formulations.
The strongest cross-licensing or litigation risk typically occurs where an accused product matches:
- EC/HPMC coat polymers,
- MCC “non-water-swellable” core,
- and coat solids percentage and polymer viscosities.
Key Takeaways
- US 4,138,475 claim 1 protects a sustained-release product that is specifically a hard gelatin capsule containing film-coated propranolol-loaded spheroids with a non-water-swellable MCC core and a film coat of ethylcellulose + HPMC.
- The independent claim is product-by-structure with tight compositional limits, especially propranolol wt% (40–65%) and non-water-swellable MCC.
- The dependent claims add high-resolution constraints: core ratio (claim 2), coat solids % (claim 3), polymer viscosity grades (claims 4 and 5), EC:HPMC ratio (claim 6), plasticizer cap (claim 7), and capsule strength ranges (claims 8 and 9).
- The narrowest infringement mapping is claim 9, which fixes both core composition (60/40) and coat composition (90% EC / 10% HPMC with specific viscosities) plus coat weight 9–10% and 160 mg propranolol HCl per capsule.
FAQs
1) Does US 4,138,475 cover tablets or only capsules?
The claim language specifies a hard gelatin capsule containing the film-coated spheroids, so coverage is tied to capsule multiparticulates rather than tablets.
2) If a product uses ethylcellulose and HPMC but different polymer viscosities, is it still covered?
Claim 1 does not require viscosity grades, but dependent claims 4 and 5 do. If viscosity differs, the product may still fall within claim 1 if other elements match.
3) Can a competitor avoid infringement by removing HPMC from the coat?
Claim 1 requires the coat to comprise ethylcellulose and HPMC; eliminating HPMC would avoid claim 1.
4) What coat solids range is explicitly claimed?
Claim 3 limits coat solids to 5–15 wt% of the coated spheroids.
5) What is the narrowest commercial-strength embodiment in the claims?
Claim 9 fixes 160 mg propranolol hydrochloride per capsule along with specific core and coat composition parameterization.
